- Intellia Therapeutics amended its bylaws effective April 7, 2026.
- Changes add a process for shareholders to cure facial deficiencies in timely notices for nominations or proposals.
- Revisions require Intellia to notify shareholders of any facial deficiencies in those notices.
- Bylaws name US federal district courts as exclusive forum for claims under Securities Act of 1933 or Securities Exchange Act of 1934, unless Intellia consents to an alternative forum in writing.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-151300), on April 10, 2026, and is solely responsible for the information contained therein.
Comments